Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
暂无分享,去创建一个
Peter Reiss | Paul A Volberding | S. Hammer | R. Schooley | M. Hirsch | D. Richman | P. Volberding | J. Montaner | J. Gatell | P. Reiss | P. Cahn | M. Fischl | S. Walmsley | J. Eron | P. Yeni | D. M. Jacobsen | Douglas D Richman | Margaret A Fischl | Pedro Cahn | Julio S G Montaner | Joseph J Eron | Martin S Hirsch | Scott M Hammer | Melanie A Thompson | Donna M Jacobsen | Robert T Schooley | Sharon Walmsley | M. Thompson | Jose M Gatell | Patrick G Yeni | M. Hirsch
[1] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[2] M. King,et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. , 2008, The Journal of infectious diseases.
[3] P. Sullivan,et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. , 2008, Annals of internal medicine.
[4] Lynne Peeples,et al. Class-sparing regimens for initial treatment of HIV-1 infection. , 2008, The New England journal of medicine.
[5] D. Burger,et al. Use of therapeutic drug monitoring in HIV disease , 2008, Current opinion in HIV and AIDS.
[6] O. Kirk,et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.
[7] J. Currier,et al. Risk of myocardial infarction and nucleoside analogues , 2008, The Lancet.
[8] J. Gatell,et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. , 2008, The Journal of infectious diseases.
[9] A. Phillips,et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. , 2008, The Journal of infectious diseases.
[10] J. Montaner,et al. Hepatotoxicity of nevirapine in virologically suppressed patients according to gender and CD4 cell counts * , 2008, HIV medicine.
[11] C. Katlama,et al. Pharmacokinetics, Safety, and Efficacy of Tipranavir Boosted With Ritonavir Alone or in Combination With Other Boosted Protease Inhibitors as Part of Optimized Combination Antiretroviral Therapy in Highly Treatment-Experienced Patients (BI Study 1182.51) , 2008, Journal of acquired immune deficiency syndromes.
[12] D. Kuritzkes,et al. Efavirenz-based regimens in treatment-naive patients with a range of pretreatment HIV-1 RNA levels and CD4 cell counts. , 2008, The Journal of infectious diseases.
[13] B. Neal. Quantifying the Importance of Interleukin-6 for Coronary Heart Disease , 2008, PLoS medicine.
[14] Vilmundur Gudnason,et al. Long-Term Interleukin-6 Levels and Subsequent Risk of Coronary Heart Disease: Two New Prospective Studies and a Systematic Review , 2008, PLoS medicine.
[15] Spread programme,et al. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes , 2008, AIDS.
[16] Birgit Grund,et al. Earlier initiation of antiretroviral therapy in treatment-naïve patients: implications of results of treatment interruption trials , 2008, Current opinion in HIV and AIDS.
[17] Richard D Moore,et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals , 2008, AIDS.
[18] Richard D Moore,et al. A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort. , 2008, AIDS patient care and STDs.
[19] Nina Friis-Møller,et al. Incidence and Risk Factors for New-Onset Diabetes in HIV-Infected Patients , 2008, Diabetes Care.
[20] S. Mallal,et al. HLA-B*5701 screening for hypersensitivity to abacavir. , 2008, The New England journal of medicine.
[21] Andrew Schaefer,et al. Influence of Alternative Thresholds for Initiating HIV Treatment on Quality-Adjusted Life Expectancy: A Decision Model , 2008, Annals of Internal Medicine.
[22] L. Kuller,et al. Elevated Levels of Interleukin-6 and D-dimer Are Associated with and Increased Risk of Death in Patient with HIV , 2008 .
[23] J. Hammond,et al. Efficacy and Safety of Atazanavir, With or Without Ritonavir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients , 2008, Journal of acquired immune deficiency syndromes.
[24] Gemma Navarro,et al. Determinants of HIV Progression and Assessment of the Optimal Time to Initiate Highly Active Antiretroviral Therapy: PISCIS Cohort (Spain) , 2008, Journal of acquired immune deficiency syndromes.
[25] J. Lundgren,et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV * , 2008, HIV medicine.
[26] Philippe Flandre,et al. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients , 2008, AIDS.
[27] B. Gazzard,et al. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis , 2008, Journal of acquired immune deficiency syndromes.
[28] J. Chmiel,et al. Initiation of Antiretroviral Therapy at CD4 Cell Counts ≥350 Cells/mm3 Does Not Increase Incidence or Risk of Peripheral Neuropathy, Anemia, or Renal Insufficiency , 2008, Journal of acquired immune deficiency syndromes.
[29] R. Weber,et al. Incidence and risk factors for new onset diabetes mellitus in HIV infected patients: the D:A:D study , 2008 .
[30] Douglas D. Richman,et al. Antiretroviral Treatment of Adult HIV Infection , 2008 .
[31] C. Katlama,et al. Pooled 48-Week analysis of DUET-1 and DUET-2: durable efficacy and safety results of etravirine (ETR; TMC125) in treatment-experienced HIV-infected patients , 2008 .
[32] D. Cattaneo,et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer , 2007, AIDS.
[33] P. Volberding,et al. Racial differences in end-stage renal disease rates in HIV infection versus diabetes. , 2007, Journal of the American Society of Nephrology : JASN.
[34] M. Levine,et al. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[35] D. Ward,et al. Treatment response to ritonavir-boosted tipranavir versus ritonavir-boosted lopinavir in HIV-1 patients with higher lopinavir mutation scores , 2007, AIDS.
[36] I. Frank,et al. Steady‐state pharmacokinetics of once‐daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers * , 2007, HIV medicine.
[37] F. de Wolf,et al. Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. , 2007, The Journal of antimicrobial chemotherapy.
[38] C. Crumpacker,et al. Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study , 2007, Journal of acquired immune deficiency syndromes.
[39] C. Katlama,et al. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.
[40] J. Montaner,et al. TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals. , 2007, AIDS patient care and STDs.
[41] B. Gazzard,et al. Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count , 2007, AIDS.
[42] R. Parker,et al. Long-Term Body Fat Outcomes in Antiretroviral-Naive Participants Randomized to Nelfinavir or Efavirenz or Both Plus Dual Nucleosides: Dual X-Ray Absorptiometry Results From A5005s, a Substudy of Adult Clinical Trials Group 384 , 2007, Journal of acquired immune deficiency syndromes.
[43] S. Bangalore,et al. Fixed-dose combinations improve medication compliance: a meta-analysis. , 2007, The American journal of medicine.
[44] A. Hill,et al. Should we now adopt the HIV-RNA < 50 copy endpoint for clinical trials of antiretroviral-experienced as well as naive patients? , 2007, AIDS.
[45] R. Haubrich,et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.
[46] K. Ruxrungtham,et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial , 2007, The Lancet.
[47] M. Falster,et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis , 2007, The Lancet.
[48] Lin Shen,et al. The HBV drug entecavir - effects on HIV-1 replication and resistance. , 2007, The New England journal of medicine.
[49] S. Staszewski,et al. Association of Saquinavir Plasma Concentrations with Side Effects but Not with Antiretroviral Outcome in Patients Infected with Protease Inhibitor-Susceptible Human Immunodeficiency Virus Type 1 , 2007, Antimicrobial Agents and Chemotherapy.
[50] B. Gazzard,et al. The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years , 2007, AIDS.
[51] C. Fraser,et al. CD4 Cell Counts of 800 Cells/mm3 or Greater After 7 Years of Highly Active Antiretroviral Therapy Are Feasible in Most Patients Starting With 350 Cells/mm3 or Greater , 2007, Journal of acquired immune deficiency syndromes.
[52] J. Sterne,et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies , 2007, AIDS.
[53] A. de Ruiter,et al. Steady-state lopinavir levels in third trimester of pregnancy , 2007, AIDS.
[54] A. Mocroft,et al. Risk of Discontinuation of Nevirapine due to Toxicities in Antiretroviral-Naive and -Experienced HIV-Infected Patients with High and Low CD4+ T-Cell Counts , 2007, Antiviral therapy.
[55] O. Kirk,et al. Class of antiretroviral drugs and the risk of myocardial infarction. , 2007, The New England journal of medicine.
[56] R. Haubrich,et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials , 2007, The Lancet.
[57] V. Soriano,et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. , 2007, The Journal of infectious diseases.
[58] P. Harrigan,et al. Superior virological response to boosted protease inhibitor‐based highly active antiretroviral therapy in an observational treatment programme , 2007, HIV medicine.
[59] D. Podzamczer,et al. Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine: 96-Week Results of a Randomized Study , 2007, Journal of acquired immune deficiency syndromes.
[60] Richard D Moore,et al. Risk of Non-AIDS-Related Mortality May Exceed Risk of AIDS-Related Mortality Among Individuals Enrolling Into Care With CD4+ Counts Greater Than 200 Cells/mm3 , 2007, Journal of acquired immune deficiency syndromes.
[61] Richard D Moore,et al. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[62] B. Gazzard,et al. When should antiretroviral therapy for HIV be started? , 2007, BMJ : British Medical Journal.
[63] B. Thiers,et al. CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .
[64] When should antiretroviral therapy for HIV be started? , 2007, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[65] C. Kovacs,et al. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.
[66] B. Gazzard,et al. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Versus Fixed-Dose Zidovudine/Lamivudine and Efavirenz in Antiretroviral-Naive Patients: Virologic, Immunologic, and Morphologic Changes-A 96-Week Analysis , 2006, Journal of acquired immune deficiency syndromes.
[67] J Darbyshire,et al. CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.
[68] Tobias Sing,et al. Determining Human Immunodeficiency Virus Coreceptor Use in a Clinical Setting: Degree of Correlation between Two Phenotypic Assays and a Bioinformatic Model , 2006, Journal of Clinical Microbiology.
[69] D. Dieterich,et al. Zidovudine use but not weight‐based ribavirin dosing impacts anaemia during HCV treatment in HIV‐infected persons , 2006, Journal of viral hepatitis.
[70] W. Kreuz,et al. Need for therapeutic drug monitoring in HIV-1 infected children receiving efavirenz doses according to international guidelines. , 2006, European journal of medical research.
[71] John T Brooks,et al. Mortality in the Highly Active Antiretroviral Therapy Era: Changing Causes of Death and Disease in the HIV Outpatient Study , 2006, Journal of acquired immune deficiency syndromes.
[72] O. Kirk,et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. , 2006, Archives of internal medicine.
[73] Christopher D Pilcher,et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. , 2006, JAMA.
[74] D. Ward,et al. Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles. , 2006, AIDS patient care and STDs.
[75] C. Katlama,et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.
[76] S. Mallal,et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[77] C. Giaquinto,et al. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration. , 2006, The Journal of antimicrobial chemotherapy.
[78] J. Cristol,et al. Is tenofovir involved in hypophosphatemia and decrease of tubular phosphate reabsorption in HIV-positive adults? , 2006, The Journal of infection.
[79] O. Kirk,et al. The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study , 2006, HIV medicine.
[80] S. Khoo,et al. Pharmacologic Optimization of Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors (POPIN)-A Randomized Controlled Trial of Therapeutic Drug Monitoring and Adherence Support , 2006, Journal of acquired immune deficiency syndromes.
[81] Kholoud Porter,et al. Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion , 2006, AIDS.
[82] J. Sterne,et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.
[83] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[84] Martin Fisher,et al. An Open-Label, Randomized Comparative Pilot Study of a Single-Class Quadruple Therapy Regimen versus a 2–Class Triple Therapy Regimen for Individuals Initiating Antiretroviral Therapy , 2006, Antiviral therapy.
[85] Michael S Saag,et al. Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .
[86] N. Snowden,et al. The development of hypophosphataemic osteomalacia with myopathy in two patients with HIV infection receiving tenofovir therapy , 2005, HIV medicine.
[87] J. Castilla,et al. Effectiveness of Highly Active Antiretroviral Therapy in Reducing Heterosexual Transmission of HIV , 2005, Journal of acquired immune deficiency syndromes.
[88] Anke Richter,et al. HIV Antiretroviral Treatment: Early Versus Later , 2005, Journal of acquired immune deficiency syndromes.
[89] K. Tashima,et al. Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[90] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[91] D. Cooper,et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study , 2004, AIDS.
[92] J. Connor,et al. Quality Assurance Program for Clinical Measurement of Antiretrovirals: AIDS Clinical Trials Group Proficiency Testing Program for Pediatric and Adult Pharmacology Laboratories , 2004, Antimicrobial Agents and Chemotherapy.
[93] Richard D Moore,et al. Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study , 2004, AIDS.
[94] J. Bartlett. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4 lymphocyte counts <350 cells/µL , 2004 .
[95] A. Hsu,et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.
[96] B. Mamlin,et al. Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients. , 2004, Clinical nephrology.
[97] Timothy R Sterling,et al. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. , 2003, The Journal of infectious diseases.
[98] J. Neaton,et al. Grade 4 Events Are as Important as AIDS Events in the Era of HAART , 2003, Journal of acquired immune deficiency syndromes.
[99] S. Buskin,et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts <350 cells/microL. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[100] B. Gazzard,et al. A 48‐Week, Randomized, Open‐Label Comparison of Three Abacavir‐Based Substitution Approaches in the Management of Dyslipidemia and Peripheral Lipoatrophy , 2003, Journal of acquired immune deficiency syndromes.
[101] Maria Deloria-Knoll,et al. Survival Benefit of Initiating Antiretroviral Therapy in HIV-Infected Persons in Different CD4+ Cell Strata , 2003, Annals of Internal Medicine.
[102] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[103] R. Weber,et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 106/l , 2002, AIDS.
[104] L. Svetkey,et al. Protease inhibitors are associated with a slowed progression of HIV-related renal diseases. , 2002, Clinical nephrology.
[105] Mardge H. Cohen,et al. Predictors of proteinuria and renal failure among women with HIV infection. , 2002, Kidney international.
[106] V. D’Agati,et al. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. , 2001, The New England journal of medicine.
[107] S. Hammer,et al. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. , 2000, JAMA.
[108] T. Quinn,et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.
[109] Douglas D. Richman,et al. Antiretroviral therapy for HIV infection in 1996 : Recommendations of an international panel , 1996 .